Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.71 |
| ▸ | PDGFRA | P16234 | 7/20 | 0.71 |
| ▸ | AXL | P30530 | 2/20 | 0.70 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | RET | P07949 | 1/20 | 0.65 |
| ▸ | KIT | P10721 | 3/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.61 |
| ▸ | AURKA | O14965 | 1/20 | 0.61 |
| ▸ | LCK | P06239 | 1/20 | 0.61 |
| ▸ | CSF1R | P07333 | 1/20 | 0.61 |
| ▸ | MET | P08581 | 1/20 | 0.61 |
| ▸ | BRAF | P15056 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1472517 | 0.90 | KDR (0.66) | KDRPDGFRAAXLFGFR2KIT | |
| SCHEMBL3227406 | 0.89 | KDR (0.73) | KDRPDGFRAAXLFGFR2KIT | |
| SCHEMBL1474146 | 0.88 | AXL (0.58) | KDRPDGFRAAXLFGFR2KIT | |
| SCHEMBL1471406 | 0.88 | MAPT (0.69) | KDRPDGFRAAXLFGFR2MEN1 | |
| SCHEMBL1472125 | 0.87 | FGFR2 (0.60) | KDRPDGFRAAXLFGFR2RET | |
| SCHEMBL1472124 | 0.87 | FGFR2 (0.60) | KDRPDGFRAAXLFGFR2RET | |
| SCHEMBL12750547 | 0.86 | AXL (0.56) | KDRPDGFRAAXLFGFR2KIT | |
| SCHEMBL4367074 | 0.86 | MET (0.60) | KDRPDGFRAAXLFGFR2MEN1 | |
| SCHEMBL1471959 | 0.85 | AXL (0.60) | KDRPDGFRAAXLFGFR2MEN1 | |
| SCHEMBL12750550 | 0.85 | FGFR2 (0.61) | KDRPDGFRAAXLFGFR2KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125780-B1 | SUBSTITUTED HETEROCYCLES AND METHODS OF USE | AMGEN INC (US) | 2012-08-29 | — | — | EP | disclosed |
| EP-2125780-B1 | SUBSTITUTED HETEROCYCLES AND METHODS OF USE | AMGEN INC (US) | 2012-08-29 | — | — | EP | disclosed |
| US-7915287-B2 | Use treating hepatocyte growth factor (HGF)-mediated diseases such as cancer; inhibitors of c-Met; e.g. 3-(3-fluoro-4-(7-methoxyquinolin-4-yloxy)phenylamino)-N-phenylpyrazine-2-carboxamide | AMGEN INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915287-B2 | Use treating hepatocyte growth factor (HGF)-mediated diseases such as cancer; inhibitors of c-Met; e.g. 3-(3-fluoro-4-(7-methoxyquinolin-4-yloxy)phenylamino)-N-phenylpyrazine-2-carboxamide | AMGEN INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915287-B2 | Use treating hepatocyte growth factor (HGF)-mediated diseases such as cancer; inhibitors of c-Met; e.g. 3-(3-fluoro-4-(7-methoxyquinolin-4-yloxy)phenylamino)-N-phenylpyrazine-2-carboxamide | AMGEN INC. (US) | 2011-03-29 | — | — | US | disclosed |
| EP-2125780-A1 | SUBSTITUTED HETEROCYCLES AND METHODS OF USE | Amgen Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080200464-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080200464-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080200464-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2008-08-21 | — | — | US | disclosed |
| WO-2008079294-A1 | SUBSTITUTED HETEROCYCLES AND METHODS OF USE | AMGEN INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200464-A1 | Substituted heterocycles and methods of use | HGF, HGFAC, MET | KDR 231/4885PDGFRA 26/4885AXL 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.